Indole Derivatives Modulate Alpha-7 nAChR Without Desensitization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current α7 nicotinic acetylcholine receptor (nAChR) agonists face challenges due to rapid desensitization and activation followed by blockade, leading to potential antagonism, and chronic treatment may result in receptor desensitization, limiting their therapeutic efficacy in conditions like schizophrenia and cognitive impairment.
Innovation Solution
Development of novel indole derivatives acting as positive allosteric modulators (PAMs) that enhance α7 nAChR activation without activating the receptor on their own, thereby avoiding desensitization and allowing for sustained modulation of the receptor.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If α7 nAChR agonists are used to treat CNS diseases, then receptor activation and therapeutic effect are improved, but rapid desensitization and receptor blockade occur leading to reduced efficacy
Solution Approach 1:
Instead of using direct agonists that activate the receptor and subsequently cause desensitization, the invention inverts the approach by using positive allosteric modulators that enhance endogenous agonist effects without directly activating the receptor. This indirect modulation avoids the desensitization pathway while maintaining therapeutic benefits.
Solution Approach 2:
The patent introduces positive allosteric modulators as intermediary substances that bind to a distinct allosteric site on the α7 nAChR. These modulators do not directly activate the receptor but instead enhance the binding and effects of endogenous acetylcholine, serving as a mediator between the endogenous ligand and the receptor activation process, thereby avoiding desensitization.
2Duration of action of moving object
If chronic treatment with α7 nAChR agonists is administered, then initial therapeutic effects are achieved, but receptor desensitization limits long-term efficacy
Solution Approach 1:
The invention inverts the conventional agonist approach by employing positive allosteric modulators that work indirectly through enhancing endogenous ligand effects. This inverted mechanism allows for chronic administration without the progressive desensitization that plagues direct agonists, thereby maintaining reliable therapeutic efficacy over extended treatment periods.
Solution Approach 2:
Positive allosteric modulators enable continuous useful action by consistently enhancing endogenous agonist effects without undergoing desensitization. The modulators maintain their facilitatory effect on receptor activation throughout chronic treatment, ensuring continuous therapeutic benefit without the efficacy decline observed with conventional agonists.
3Speed
If direct agonists are used to activate α7 nAChR, then receptor activation is achieved, but subsequent blockade and antagonism occur
Solution Approach 1:
The patent employs positive allosteric modulators as intermediaries that facilitate receptor activation indirectly. These modulators bind to allosteric sites and enhance the effects of endogenous agonists without directly competing for the orthosteric binding site, thereby avoiding the blockade and antagonism that occur with direct agonist use while still achieving rapid receptor activation.
Solution Approach 2:
Instead of directly activating the receptor with agonists that subsequently cause blockade, the invention inverts the mechanism by using modulators that enhance endogenous ligand effects. This indirect approach eliminates the harmful blockade effect while preserving the beneficial rapid activation through endogenous acetylcholine.
Data Source
AI summary
This invention relates to modulation of the a7 nicotinic acetylcholine receptor (nAChR) by a compound of List A or a salt thereof which may be represented by N-[(2-Trifluoromethyl-1H-indol-5-yl)methyl]-5-(trifluoromethyl)-2-pyrimidinecarboxarnide.